The “SARS-Cov-2 Vaccination Strategies In Previously Hospitalized And Recovered COVID-19 Patients” clinical trial known as “VATICO” is assessing the optimal timing and number of mRNA COVID-19 vaccinations for patients discharged after hospitalization for SARS-CoV-2 infection. This trial is a sub-study of the TICO (Therapeutics for Inpatients with COVID-19) study which is a Phase 3 randomized, blinded, controlled platform trial that allows investigational agents to be added and dropped during the course of the study for efficient testing of new agents against control (i.e., placebo + SOC) within the same trial infrastructure.